PROCESS Of OBTAINING ACROLEIN BY CATALYTIC GLYCERIN OR GLYCEROL DEHYDRATION

Un procédé continu d'obtention d'acroléine par déshydratation catalytique de glycérol ou de glycérine, en présence d'un catalyseur acide, ledit procédé comprenant la régénération concomitante dudit catalyseur et étant réalisé dans un réacteur à lit fluidisé, ledit réacteur comprenant deux zones, une première zone, ou zone inférieure, dite de régénération du catalyseur dans laquelle un gaz de fluidisation comprenant de l'oxygène est introduit et une seconde zone, ou zone supérieure, dite de réaction dans lequel le glycérol ou la glycérine est introduit et converti en acroléine.

DEVICE OF DRYING POST-NETTOYAGE Of a CONTAINER OF PLATES SEMICONDUCTRICES

RESONATEUR-AMPLIFICATEUR HIGH VOLTAGE OF STRUCTURE OPTIMISEE FOR IGNITION SYSTEM RADIO FREQUENCY

METHOD OF OPERATING A VOLTAGE REGULATOR REGULATES THE OPERATION OF A RADIOFREQUENCY SPARK PLUG

"Plug Type Ignition Spark Rf Integrated Cooling"

PREVENTION AGAINST A SHORT-CIRCUIT OF CANDLE RF

"Plug Type Ignition Spark RF Weakening Embedded"

SPARK PLUG, IGNITION SYSTEM, ENGINE AND IGNITION METHOD FOR THE ENGINE.

L'invention concerne une bougie (1) comprenant : ▪ une enveloppe (3), ▪ un isolateur (4), ▪ une électrode (5) traversant l'isolateur (4) et comportant une pointe (6), ▪ un résonateur (7) comportant une borne d'alimentation (70), une borne de sortie (72) confondue avec l'électrode (5), un bobinage (73) logé dans l'enveloppe (3), une borne de masse (71) et une capacité (74), Selon l'invention, la distance entre le bobinage (73) et la pointe (6) est comprise entre 2 cm et 6 cm, la surtension (V) est égale ou inférieure à 30 KV, la pointe (6) comporte une tête (61) présentant un rayon (R1) de courbure égal ou inférieur à 250 µm, et le résonateur (7) présente une fréquence propre (F) comprise entre 3 MHz et 10 MHz. L'invention concerne aussi un système d'allumage (10) et un moteur (9) utilisant la bougie (1) ainsi qu'un procédé d'allumage dudit moteur (9).

CANDLE, SYSTEM IGNITION, ENGINE AND PROCESS Of LIGHTING FOR the ENGINE.

REAR WINDOW OPENING FOR MOTOR VEHICLE.

Multi-filament radio frequency sparking type spark plug for positive ignition thermal engine, has starter arranged in determined zone such that rupture of body under pressure does not present risks for operator during tightening process

L'invention propose une bougie (10) d'allumage de type à étincelle radiofréquence multi-filamentaire pour un moteur thermique à allumage commandé, comprenant un corps (12) cylindrique tubulaire (12) dont au moins une partie reçoit coaxialement de l'extérieur vers l'intérieur au moins un isolant (14) gazeux sous pression élevée occupant un volume sensiblement tubulaire et au moins un bobinage (16) cylindrique en fil émaillé qui est apte à être parcouru par un courant d'intensité élevée et dont une extrémité est lié électriquement à une électrode (18) de la bougie, ladite bougie (10) étant apte à être serrée dans une culasse (11) de moteur thermique, caractérisée en ce qu'au moins une partie du corps (12) cylindrique tubulaire comporte une amorce de rupture qui est apte à se rompre dès lors que le corps (12) sous pression est soumis à un couple dit "de rupture" et qui est agencée dans une zone (28) déterminée du corps (12) ne présentant pas de risques pour un opérateur.

DEVICE AND METHOD FOR CHARACTERIZING A LIGHT BEAM

Un aspect de l'invention concerne un dispositif de caractérisation d'un faisceau de lumière comportant : - une optique séparatrice définissant un premier chemin optique pour un premier sous-faisceau du faisceau de lumière et un deuxième chemin optique pour un deuxième sous-faisceau du faisceau de lumière ; - une première optique agencée sur le premier chemin optique et ayant un premier rayon de courbure de manière que le premier sous-faisceau en sortie de la première optique, dit « faisceau de référence », présente des fronts d'onde d'un premier type ; - une deuxième optique agencée sur le deuxième chemin optique et ayant un deuxième rayon de courbure de manière que le deuxième sous-faisceau en sortie de la deuxième optique, dit « faisceau à caractériser », présente des fronts d'onde d'un deuxième type ; - un moyen de contrôle d'un délai temporel τ entre le faisceau de référence et le faisceau à caractériser ; - une optique recombinatrice pour la recombinaison du faisceau de référence et ...

Multi-filament radio frequency sparking type spark plug for positive ignition thermal engine, has winding whose section covers cavity, which is traversed by coolant adapted to allow cooling of winding by natural convection

L'invention propose une bougie (10) d'allumage de type à étincelle radiofréquence multi-filamentaire pour un moteur thermique à allumage commandé, comprenant un corps cylindrique tubulaire (12) recevant coaxialement à un isolant tubulaire (14) au moins un bobinage (16) cylindrique en fil émaillé apte à être parcouru par un courant d'intensité élevée, et une électrode (18) de la bougie liée électriquement audit bobinage, caractérisée en ce qu'au moins un tronçon (28) dudit bobinage (16) abrite une cavité (30) qui est parcourue par un fluide de refroidissement apte à permettre le refroidissement dudit bobinage par convection.

Method for controlling internal combustion engine of motor vehicle, involves determining operating frequency of radiofrequency spark plug of cylinder of engine from measurement of value representative of maximum pressure angle of cylinder

The method involves energizing a radiofrequency spark plug at excitation frequency (E1-1), where the excitation frequency is varied in a combustion stage (E1). A value representative of a maximum pressure angle of a cylinder associated with the excitation frequency is measured (E1-2) at a corresponding combustion stage. Operating frequency of the radiofrequency spark plug of the cylinder of an engine is determined (E3) from the measurement of value representative of the maximum pressure angle of the cylinder. Independent claims are also included for the following: (1) a motor vehicle (2) a computer program comprising a set of instructions for performing a method for controlling an engine of a motor vehicle.

PLUG SPARK EQUIPEE OF MEANS OF PREVENTION OF the SHORT-CIRCUITS

L'invention concerne une bougie d'allumage du type plasma à radiofréquence comprenant : - un culot cylindrique (2) d'axe principal (X) formé dans un premier matériau électriquement conducteur, - une électrode centrale (4) formée dans un second matériau conducteur et s'étendant selon l'axe principal (X) et, - un corps (3), formé dans un matériau diélectrique, disposé entre ledit culot (2) et ladite électrode (4), en présentant une face latérale interne (3b) de contact avec l'électrode et au-delà de laquelle une portion d'extrémité (4a) de l'électrode (4) fait saillie, caractérisée en ce que ledit corps (3) comporte au moins une cavité annulaire (30) d'axe (X), ménagée sur sa face latérale (3b) de contact avec l'électrode (4) de façon à modifier localement les lignes du champ électrostatique à la jonction entre la face externe (3a) du dit corps et l'électrode (4).

SPARK PLUG FOR INTERNAL COMBUSTION ENGINE

A sparkplug including an induction coil and an electrode. The induction coil includes two end portions, the electrode extending in a continuation of one of the two end portions. The induction coil includes a conducting wire wound to form a succession of turns, the one of the two end portions having a terminal turn connected to the electrode. The one of the two end portions includes a plurality of coaxial end turns that extend between the terminal turn and an upstream turn, and the terminal turn has a diameter smaller than the diameter of the upstream turn so to reduce strength of the electric field induced in the one of said two end portions near the terminal turn.

PROCESS Of OBTAINING ACROLEIN BY CATALYTIC GLYCERIN OR GLYCEROL DEHYDRATION

PLUGS SPARK FOR the INTERNAL COMBUSTION ENGINE Of a MOTOR VEHICLE

SPARK PLUG FOR INTERNAL COMBUSTION ENGINE

PLUG SPARK EQUIPEE OF MEANS OF PREVENTION OF the SHORT-CIRCUITS

DEVICE AND METHOD FOR GENERATING A DATABASE RELATING TO DRUGS

L'invention propose un dispositif de génération (100) d'une base de données de médicaments pivot (10) implémenté dans un système informatique, le dispositif comprenant : -une unité d'extraction (3) configurée pour extraire les données d'un ensemble de sources de données de médicaments élémentaires (2), les sources de données de médicaments élémentaires stockant des données relatives aux médicaments, chaque source de donnée élémentaire étant associée à une représentation des données ; - une unité de structuration (4) configurée pour structurer les données extraites en appliquant une ontologie pivot (40) aux données extraites, l'ontologie pivot définissant des classes dérivées d'une ou plusieurs ontologies du médicament et des relations entre lesdites classes, ce qui fournit des données structurées associées à un graphe représentant les relations entre les classes correspondant auxdites données structurées; le dispositif étant configuré pour générer la base de données de médicament pivot ...

PREVENTION AGAINST A SHORT-CIRCUIT OF CANDLE RF

Bougie d'allumage qui comporte une électrode centrale (10), qui comprend une extrémité supérieure (18) et une extrémité inférieure (17), une pièce isolante (11), qui comprend une partie supérieure et une partie inférieure, et qui entoure l'électrode centrale (10) de façon à ce que l'extrémité inférieure (17) de l'électrode centrale dépasse de la partie inférieure de la pièce de matière isolante, un culot (12), qui comprend une partie supérieure (36), et une partie inférieure (37) comportant un tronçon d'extrémité (14), et qui entoure la pièce de matière isolante de façon à ce que la partie inférieure de la pièce de matière isolante dépasse de la partie inférieure du culot, caractérisée en ce que la pièce de matière isolante comporte une gorge annulaire (19), sur sa périphérie extérieure, au niveau de l'extrémité inférieure du culot, et en ce que le tronçon d'extrémité (14) inférieure du culot est disposé dans la gorge. Spark plug which has a central electrode (10), which comprises an upper end (18) and a lower end (17), an insulating part (11), which comprises an upper part and a lower part, and which surrounds the central electrode (10) so that the lower end (17) of the central electrode protrudes from the lower part of the insulating material part, a base (12), which comprises an upper part (36), and a lower portion (37) having an end portion (14), and surrounding the piece of insulating material so that the lower portion of the piece of insulating material protrudes from the bottom portion of the pellet, characterized in that that the piece of insulating material comprises an annular groove (19), on its outer periphery, at the lower end of the base, and in that the lower end section (14) of the base is disposed in the groove.

Internal combustion engine management method for motor vehicle, involves determining operational voltage of radio frequency spark plug of cylinder of engine from measurement representative of value of angle of maximum pressure of cylinder

The method involves determining operational voltage (E3) of a radio frequency spark plug of a cylinder of an internal combustion engine from a measurement representative of a value of angle of maximum pressure of the cylinder. A set of combustion stages is provided for the cylinder, where each combustion stage is provided with an energization step in which the spark plug is energized (E1-1) to an excitation voltage. The excitation voltage is provided differently for each of the set of combustion stages. Independent claims are also included for the following: (1) a motor vehicle (2) a recording medium comprising instructions for performing engine management method (3) a computer program comprising instructions for performing the engine management method.

DEVICE OF GENERATION OF PLASMA RADIO FREQUENCY.

SPARK PLUG FOR INTERNAL COMBUSTION ENGINE

L'invention concerne une bougie d'allumage (10) comprenant un bobinage inductif (28) et une électrode (24). Ledit bobinage inductif (28) présentant deux portions d'extrémité (30, 32) (34), ladite électrode (24) s'étendant dans le prolongement de l'une desdites deux portions d'extrémité (32). Ledit bobinage inductif (28) présentant un fil conducteur (36) enroulé en formant une succession de spires (44, 45, 58, 60), ladite une desdites deux portions d'extrémité (32) présentant une spire terminale (58) reliée à ladite électrode (24). Selon l'invention, ladite une desdites deux portions d'extrémité (32) comprend une pluralité de spires coaxiales d'extrémité (45) qui s'étendent entre ladite spire terminale (58) et une spire amont (60) ; et ladite spire terminale (58) présente un diamètre D58 inférieur au diamètre D60 de ladite spire amont (60), de manière à pouvoir réduire l'intensité du champ électrique induit dans ladite une desdites deux portions d'extrémité (32) au voisinage de ladite spire ...

Formulations

In a metered dose inhaler, comprising a canister and metering valve, containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant, a method of reducing deposition of particles on the surfaces of the canister and the metering valve, the method comprising the step of adding a wetting agent to the formulation. 1. In a metered dose inhaler , comprising a canister and metering valve , containing a suspension aerosol formulation comprising particles of formoterol fumaratc dihydrate and fluticasone propionate suspended in an HFA propellent , a method of reducing deposition of particles on the surfaces of the canister and the metering valve , the method comprising the step of adding a wetting agent to the formulation.2. A method according to claim 1 , wherein the wetting agent is selected from the group consisting of ethanol claim 1 , diols or polyols claim 1 , such as propylene glycol claim 1 , glycerol claim 1 , butandiol and mixtures thereof.3. A method according to wherein the wetting agent is ethanol.4. A method according to wherein the wetting agent is employed in an amount of less than 2% by weight based on the total weight of the suspension aerosol formulation.5. A method according to wherein the wetting agent is employed in an amount of 1.99 to 0.01% by weight based on the total weight of the suspension aerosol formulation.6. A method according to wherein the wetting agent is employed in an amount of 1.5% to 1.0% by weight based on the total weight of the suspension aerosol formulation.7. A method according to wherein die HFA propellent is HFA 227.8. A method according to wherein the formoterol fumarate dihydratc is employed in an amount of 0.003-0.04% by weight9. A method according to wherein fluticasone propionate is employed in an amount of 0.01-0.6% by weight.10. A method according to wherein the suspension aerosol formulation comprises a salt selected from the group ...

Improved Medicinal Aerosol Formulations

The present invention provides a medicinal aerosol suspension formulation for MDI administration, comprising: a) micronised pa-agonist; b) micronised corticosteroid; c) a siib-therapexrtic quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant. 1. A medicinal aerosol suspension formulation for MDI administration , comprising:{'sub': '2', 'a) micronised β-agonist;'}b) micronised corticosteroid;c) a sub-therapeutic quantity of a moisture-scavenger excipient; andd) a HFA propellant;wherein (a), (b) and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant.2. A medicinal aerosol suspension formulation according to claim 1 , wherein the average density of the floccules is substantially the same as the density of the propellant ±0.2 g/cm; preferably ±0.1 g/cm; and more preferably ±0.05 g/cm.3. A medicinal aerosol suspension formulation according to or claim 1 , wherein the HFA propellant is HFA 227.4. A medicinal aerosol suspension formulation according to any preceding claim claim 1 , wherein the β-agonist is formoterol fumarate or a pharmaceutically acceptable salt or derivative thereof.5. A medicinal aerosol suspension formulation according to any preceding claim claim 1 , wherein the β-agonist is present in an amount 0.003-0.04% by weight; preferably 0.04-0.03% by weight; and more preferably 0.005-0.02% by weight claim 1 , based on the total weight of the formulation.6. A medicinal aerosol suspension formulation according to any preceding claim claim 1 , wherein the corticosteroid is fluticasone propionate or a pharmaceutically acceptable salt or derivative thereof.7. A medicinal aerosol suspension formulation according to any preceding claim claim 1 , ...

Transformer with shielding rings in windings

A coil and electric shielding arrangement for a dry-type transformer includes an electric shielding device arranged at a distance from a winding, at an axial end of the winding perpendicular to a longitudinal axis of the transformer, and parallel to a top surface of a coil that is wound around the axis such that the electric shielding device covers a cross-sectional area of the winding perpendicular to the longitudinal axis. An insulation material attached to the winding and to the electric shielding device establishes a first distance between the winding and the electric shielding device along the longitudinal axis such that the winding is shielded against another electric field. The winding and the electric shielding device are casted in a block which insulates the electric shielding device from the electric field of the winding by establishing a second distance between the winding and the electric shielding device.

PROCESS FOR OBTAINING ACROLEIN BY CATALYTIC DEHYDRATION OF GLYCEROL OR GLYCERIN

A continuous process for obtaining acrolein by catalytic dehydration of glycerol or glycerin, in the presence of an acid catalyst, wherein said process comprises the concomitant regeneration of said catalyst and is carried out in a fluidized bed reactor, said reactor comprising two zones, a first zone, or lower zone, termed catalyst regeneration zone, in which a fluidization gas comprising oxygen is introduced, and a second zone, or upper zone, termed reaction zone, in which the glycerol or glycerin is introduced and converted into acrolein. 1. A continuous process for the production of acrolein by catalytic dehydration of glycerol or glycerin in the presence of an acid catalyst , characterized in that it comprises the concomitant regeneration of said catalyst and in that it is carried out in a fluidized bed reactor , said reactor comprising two regions , a first region , or lower region , referred to as region for regeneration of the catalyst , into which an oxygen-comprising fluidizing gas is introduced , and a second region , or upper region , referred to as reaction region , into which the glycerol or the glycerin is introduced and converted into acrolein.2. The process as claimed in claim 1 , characterized in that the glycerol or the glycerin is introduced in the form of an aqueous solution in a concentration varying from 10% to 90% by weight.3. The process as claimed in claim 2 , characterized in that the glycerol or glycerin solution is introduced in the vaporized form.4. The process as claimed in claim 1 , characterized in the acid catalyst is chosen from zeolites claim 1 , phosphates claim 1 , heteropolyacids claim 1 , which are optionally supported and/or doped claim 1 , catalysts of oxide or supported oxide types claim 1 , or also of the type formed of zirconias claim 1 , which are modified and/or doped.5. The process as claimed in claim 4 , characterized in that the catalyst is chosen from supported or unsupported heteropolyacids doped with at least one ...

SHORT-CIRCUIT PREVENTION IN AN RF SPARK PLUG

A spark plug including: a central electrode including an upper end and a lower end; an insulating part including an upper portion and a lower portion and surrounds the central electrode so that the lower end of the central electrode extends beyond the lower portion of the insulating part; and a cap including an upper portion and a lower portion that has an end section and that surrounds the insulating part so that the lower portion of the insulating part extends beyond the lower portion of the cap. The insulating part includes an annular groove, on the external periphery thereof, on the lower end of the cap, and the lower end section of the cap is placed in the groove. 114-. (canceled)15. A spark plug configured to be fitted in a combustion chamber of an internal combustion engine , comprising:a central electrode of cylindrical shape including a conductive material, which includes an upper end and a lower end configured to be arranged in the combustion chamber;an insulating material component substantially tubular in shape, made of an electrically insulating material that includes an upper part and a lower part, and which surrounds the central electrode over a portion of its length so that the lower end of the central electrode extends beyond the lower part of the insulating material component;a shell made of conductive material, substantially tubular in shape that includes an upper part and a lower part comprising an end segment, and which surrounds the insulating material component over a portion of its length so that the lower part of the insulating material component extends beyond the lower part of the shell;wherein the insulating material component comprises an annular groove, on its outer periphery, at the lower end of the shell, the insulating material component is covered with a layer of metalized material over its entire outer surface from its upper end up to an edge of the groove, and the lower end segment of the shell is arranged in the groove.16. The ...

SPARKPLUG FOR AN INTERNAL COMBUSTION ENGINE

A sparkplug including an induction coil and an electrode. The induction coil includes two end portions, the electrode extending in a continuation of one of the two end portions. The induction coil includes a conducting wire wound to form a succession of turns, the one of the two end portions having a terminal turn connected to the electrode. The one of the two end portions includes a plurality of coaxial end turns that extend between the terminal turn and an upstream turn, and the terminal turn has a diameter smaller than the diameter of the upstream turn so to reduce strength of the electric field induced in the one of said two end portions near the terminal turn. 110-. (canceled)11. A sparkplug comprising:an induction coil; anda central electrode coupled to the induction coil;the induction coil including, in order from an electrical connection terminal of the sparkplug, a first end portion, a central portion, and a second end portion;the central electrode extending in line with the second end portion and away from the central portion;the induction coil including a conducting wire wound helically while forming a succession of coaxial turns, the second end portion having a terminal turn situated opposite the central portion and connected to the central electrode, the induction coil configured to produce an electrical field induced in the second end portion;wherein the second end portion comprises a plurality of coaxial end turns that extend axially between the terminal turn and an upstream turn situated toward the central portion; andwherein the terminal turn has a diameter smaller than the diameter of the upstream turn, while the turns of the plurality of coaxial end turns have a radius of curvature that reduces progressively between the upstream turn and the terminal turn so as to be able to reduce intensity of the electrical field induced in the second end portion in a vicinity of the terminal turn.12. The sparkplug as claimed in claim 11 , wherein the turns of ...

Camera Based Hover Detection for Touch-Based Mobile Devices

The disclosure generally describes computer-implemented methods, software, and systems for providing camera-based hover detection for touch-based mobile devices. One computer-implemented method includes receiving image data from at least one image capture device associated with a particular client device, comparing, by operation of a computer, the received image data to existing image data, wherein the existing image data partially includes extrapolated imaged data, determining that the received image data does not compare with existing image data and transmitting the received image data to a server for post-processing, processing, by operation of a computer, post-processed image data received from the server, wherein the processing includes updating a user configuration with the post-processed image data, and generating a hover event based upon the received image data. 1. A computer-implemented method , comprising:receiving image data from at least one image capture device associated with a particular client device;comparing, by operation of a computer, the received image data to existing image data, wherein the existing image data partially includes extrapolated imaged data;determining that the received image data does not compare with existing image data and transmitting the received image data to a server for post-processing;processing, by operation of a computer, post-processed image data received from the server, wherein the processing includes updating a user configuration with the post-processed image data; andgenerating a hover event based upon the received image data.2. The computer-implemented method of claim 1 , further comprising post-processing the received image data on the server.3. The computer-implemented method of claim 2 , wherein the post-processing further comprises extrapolating additional display coordinate points and display-standoff values for the received image data.4. The computer-implemented method of claim 2 , further comprising ...

FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

Liquid formulations of GLP-2 analogues are described that make it possible to include a preservative while allowing the formulation to be stabilised for long term storage as liquids and/or as multi-dose liquid formulations. The development of these formulations is base on the finding that that reducing the pH of the formulation to below 7.0, e.g. to a pH between about pH 5.0 and about 6.8, was able to offset the effect that the addition of a preservative such as meta-cresol has on the physical stability of the formulation. Additionally, the addition of an excipient such as propylene glycol was shown to be able to offset the effect that the addition of a preservative, such as meta-cresol, has on the physical stability of the formulation. This opens up the possibility of being able to deliver the GLP-2 analogues as multi-dose formulations, for example allowing the use of the formulations in a drug delivery device. 3. The formulation of claim 2 , wherein the formulation comprises propylene glycol at a concentration of 20 mM to 300 mM.4. The formulation of or claim 2 , wherein the formulation comprises propylene glycol at a concentration of 50 mM to 200 mM.5. The formulation according to any one of to claim 2 , wherein the formulation is an aqueous formulation.6. The formulation according to any one of to claim 2 , wherein the formulation is stable for at least 18 months when stored at 2-8° C.7. The formulation according to any one of the preceding claims claim 2 , wherein the GLP-2 analogue is present in the formulation at a concentration of about 1 mg/mL to about 20 mg/mL.8. The formulation according to any one of the preceding claims claim 2 , wherein the GLP-2 analogue is present in the formulation at a concentration of about 2 mg/mL to about 15 mg/mL.9. The formulation according to any one of the preceding claims claim 2 , wherein the formulation is a ready-to-use formulation.10. The formulation according to any one of the preceding claims claim 2 , wherein the GLP ...

NATURAL ZEOLITE-NANOHYDROXYAPATITE COMPOUND MATERIAL, METHOD FOR PREPARING SAME AND USE THEREOF FOR REMOVING FLUORIDE FROM WATER

The present invention relates to a compound material consisting of a natural zeolite having calcium as an exchangeable cation, in which hydroxyapatite on a nanometric scale is grown in a controlled manner on the surface thereof; to the method by which said compound material is obtained; and to the use thereof for removing fluoride from water in order to make same drinkable. As a result of the aforementioned special characteristics of hydroxyapatite crystals, said material has a very high intrinsic capacity (based on the weight of hydroxyapatite) for removing fluoride. This capacity, combined with the low cost and ease of access to the materials used for preparing same, and with the straightforward nature of the method, means that said material is the perfect candidate for removing fluoride from water having high levels of this contaminant. 1. A composite material of natural zeolite-nanohydroxyapatite , comprising:a natural zeolite with an interchangeable calcium content of between 0.25 and 13% by weight, and possessing at least one system of channels whose smallest diameter is less than 0.41 nm; andHAp crystals with a total percentage of interchangeable hydroxides of at least 10%.2. The composite material according to claim 1 , wherein the natural zeolite is a natural stilbite zeolite that possesses a Ca content of 5.23% by weight.3. The composite material according to claim 1 , wherein the natural zeolite is a natural clinoptilolite zeolite claim 1 , thatpossesses a Ca content of 1.82% by weight.4. A method for obtaining the composite material according to claim 1 , wherein the growth of hydroxyapatite crystals on the natural zeolite is achieved by means of the controlled cationic interchange of the Ca of the zeolite claim 1 , and the subsequent precipitation of HAp on the surface of the zeolite in the presence of a source of phosphorus on the surface of the zeolite claim 1 , in accordance with equations 1 to 3:{'br': None, 'sub': 4', '2', '4', '4', '4, 'sup': +', ...

AMYLIN ANALOGUES

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation. 2. An amylin analogue according to wherein X1 is selected from Arg and Lys.3. An amylin analogue according to wherein X3 is Gly claim 1 , X4 is Thr claim 1 , X5 is Ala and/or X6 is Thr.4. An amylin analogue according to wherein X3 is Gly claim 3 , X4 is Thr claim 3 , X5 is Ala and X6 is Thr.5. An amylin analogue according to wherein X14 is selected from His claim 1 , Asp and Aad.6. An amylin analogue according wherein X17 is Gln.7. An amylin analogue according to wherein X19-X20 is selected from Ser-Ser and Thr-Thr claim 1 , or is absent8. An amylin analogue according to wherein X32 is Val claim 1 , X35 is Asn and/or X37 is Hyp.10. An amylin analogue according to wherein X14 is Aad claim 8 , X19-X20 is Ser-Ser and X27 is Leu.11. An amylin analogue according to wherein one of the residues at position X2 and X7 is selected from Asp claim 1 , Glu and Aad claim 1 , and the other is selected from Dap claim 1 , Dab claim 1 , Orn claim 1 , Lys and hLys.12. An amylin analogue according to wherein X2 is selected from Asp claim 11 , Glu and Aad claim 11 , and X7 is selected from Dap claim 11 , Dab claim 11 , Orn claim 11 , Lys and hLys.13. An amylin analogue according to wherein:X2 is Asp and X7 is Lys;X2 is Asp and X7 is Orn;X2 is Asp and X7 is Dab;X2 is Asp and X7 is hLys;X2 is Dap and X7 is Aad;X2 is Glu and X7 is Dab; orX2 is Dab and X7 is Glu.14. An amylin analogue according to wherein:X2 is Asp and X7 is Lys; orX2 is Asp and X7 is Orn.15. An amylin analogue according to wherein X14 is selected from Asp and Aad.17. An amylin analogue according to wherein R1 is M or M-L ...

PORTABLE AND TRACKABLE SECURITY BOX AND METHOD FOR DELIVERING AND TRACKING SECURITY BOX

A shipping box system and method are provided in which a shipping box has a container having a bottom surface and a plurality of walls, the container walls forming a perimeter about a container cavity. The shipping box further has a lid having a top surface and walls, the lid walls forming a perimeter about a lid cavity. The box further provides a sensor module for determining a physical location and orientation of the container, a computations module for evaluating data retrieved from the sensor module, and a locking assembly for locking the container and the lid in a closed configuration. The container and the lid are sized to nest, such that when the lid is fixed to the container, the container cavity and the lid cavity occupy substantially the same space and the container walls and the lid walls overlap. 1. A shipping box system comprising a first shipping box having:a container having a bottom surface and a plurality of container walls extending from the bottom surface, the container walls forming a perimeter about a container cavity;a lid having a top surface and a plurality of lid walls extending from the top surface, the lid walls forming a perimeter about a lid cavity;a sensor module for determining a physical location and orientation of the container;a computations module for evaluating data retrieved from the sensor module;a locking assembly for locking the container and the lid in a closed configuration;wherein the container and the lid are sized to nest, such that when the lid is fixed to the container, the container cavity and the lid cavity occupy substantially the same space and the container walls and the lid walls overlap.2. The shipping box system of claim 1 , wherein the perimeter about the lid cavity is larger than the perimeter about the container cavity claim 1 , such that the container is nested within the lid claim 1 , and wherein the container walls and the lid walls have substantially similar heights claim 1 , such that the container is ...

ASSISTED PORTAL NAVIGATION AND CROWD-BASED FEEDBACK

The present disclosure describes methods, systems, and computer program products for assisted portal navigation and crowd-based feedback. One computer-implemented method includes processing, by operation of a computer, a hierarchy of container documents including a base-level container document and at least one active base-level content hyperlink and additional container documents associated with the at least one active base-level content hyperlink to: generate a site map specifying the hierarchy of container documents, and associate at least one generated graphical user interface (GUI) element with each container document in the hierarchy of container documents specified by the site map, receiving a hover detection event associated with the at least one active base-level content hyperlink, displaying a first-level pop-up container document including at least one first-level GUI element representing a particular additional container document associated with the one active base-level content hyperlink, and displaying a first-level detailed pop-up container document responsive to a detected hover event associated with one of the at least one first-level GUI element. 1. A computer-implemented method comprising: generate a container document site map specifying the hierarchy of container documents; and', 'associate at least one generated graphical user interface (GUI) element with each container document in the hierarchy of container documents specified by the site map;, 'processing, by operation of a computer, a hierarchy of container documents including a base-level container document and at least one active base-level content hyperlink and additional container documents associated with the at least one active base-level content hyperlink toreceiving a hover detection event associated with the at least one active base-level content hyperlink;displaying a first-level pop-up container document including at least one first-level GUI element representing a particular ...

FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES

Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described. Solid compositions comprising acetate salts of glucagon-like peptide 2 (GLP-2) analogues useful for making the liquid formulations are also described. The development of these liquid formulations is based on the finding that acetate present in the formulation that originates from the GLP-2 analogues has an effect on the viscosity of the formulation, that during long term storage at 2-8° C. of GLP-2 analogues, the concentration dependence for covalent oligomer formation is inversely dependent on increasing concentration of the GLP-2 analogue, and that GLP-2 analogues used in the formulations are not compatible with phosphate buffer commonly used in the prior art to reconstituted powdered or lyophilized GLP-2 compositions. 24-. (canceled)5. The formulation according to claim 1 , wherein the formulation is stable for at least 18 months when stored at 2-8° C.6. (canceled)7. The formulation according to claim 1 , wherein the GLP-2 analogue is present in the formulation at a concentration of about 15 mg/mL to about 25 mg/ml.8. (canceled)9. The formulation according to claim 1 , wherein the GLP-2 analogue is present in the formulation at a concentration of about 20 mg/mL.10. The formulation according to claim 1 , wherein the buffer is present in the formulation at a concentration of about 5 mM to about 25 mM.11. The formulation according to claim 1 , wherein the buffer is a histidine buffer.1218-. (canceled)19. The formulation according to claim 1 , wherein the formulation comprises the GLP-2 analogue at a concentration of about 20 mg/mL claim 1 , histidine buffer at a concentration of about 15 mM claim 1 , mannitol at a concentration of about 230 mM claim 1 , and arginine q.s. to provide a pH of about 7.0.2028-. (canceled)29. The formulation according to claim 1 , wherein the GLP-2 ...

AMYLIN ANALOGUES

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation. 2. An amylin analogue according to wherein X1 is selected from Arg and Lys.3. An amylin analogue according to wherein:(i) X3 is Gly, X4 is Thr, X5 is Ala and/or X6 is Thr;(ii) X3 is Gly, X4 is Thr, X5 is Ala and X6 is Thr;(iii) X14 is selected from His, Asp and Aad;(iv) X17 is Gln;(v) X19-X20 is selected from Ser-Ser and Thr-Thr, or is absent; or(vi) X32 is Val, X35 is Asn and/or X37 is Hyp.48-. (canceled)10. (canceled)11. An amylin analogue according to wherein one of the residues at position X2 and X7 is selected from Asp claim 1 , Glu and Aad claim 1 , and the other is selected from Dap claim 1 , Dab claim 1 , Orn claim 1 , Lys and hLys.12. (canceled)13. An amylin analogue according to wherein:X2 is Asp and X7 is Lys;X2 is Asp and X7 is Orn;X2 is Asp and X7 is Dab;X2 is Asp and X7 is hLys;X2 is Dap and X7 is Aad;X2 is Glu and X7 is Dab; orX2 is Dab and X7 is Glu.14. An amylin analogue according to wherein:X2 is Asp and X7 is Lys; orX2 is Asp and X7 is Orn.15. An amylin analogue according to wherein X14 is selected from Asp and Aad.17. An amylin analogue according to wherein Ris M or M-L-.18. An amylin analogue according to wherein M is a lipophilic substituent comprising a hydrocarbon chain having from 10 to 24 C atoms.19. An amylin analogue according to wherein the lipophilic substituent comprises a carboxylic acid group at the end of the hydrocarbon chain.20. An amylin analogue according to wherein the lipophilic substituent is a 15-carboxy-pentadecanoyl claim 19 , 17-carboxy-heptadecanoyl or 19-carboxy-nonadecanoyl moiety.21. An amylin analogue according to ...

ACYLATED GLP-1/GLP-2 DUAL AGONISTS

A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction. 1. A dual agonist or pharmaceutically acceptable salt or solvate thereof represented by the formula:{'br': None, 'sup': 1', '2, 'R—X*—R'}wherein:{'sup': '1', 'sub': '1-4', 'Ris hydrogen (Hy), Calkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl;'}{'sup': '2', 'sub': '2', 'Ris NHor OH;'}X* is a peptide H[Aib]EGSFTSELATILDψQAARDFIAWLIQHKITD;{'sup': 1', '2, 'ψ is an L or D Lys residue whose side chain is conjugated to a substituent of formula Z—Z—;'}{'sup': 1', '2, 'and Z—Z— is [17-carboxy-heptadecanoyl]-isoGlu.'}4. A pharmaceutical composition comprising the dual agonist or pharmaceutically acceptable salt or solvate thereof according to claim 1 , in admixture with a pharmaceutically acceptable carrier claim 1 , an excipient or a vehicle. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.The present application is being filed along with an Electronic Sequence Listing as an ASCII text file via EFS-Web. The Electronic Sequence Listing is provided as a file entitled 29418620_1.txt created and last saved on Nov. 13, 2018, which is approximately 113 kilobytes in size. The information in the Electronic Sequence Listing is incorporated herein by reference in its entirety in accordance with 35 U.S.C. § 1.52(e).The present invention relates to acylated compounds having agonist activity at the GLP- ...

DOCKING SYSTEM AND METHOD FOR SATELLITES

The present invention relates to a service satellite having a body, a controller and a docking unit. The docking unit includes at least two foldable, adjustable gripping arms pivotally mounted on the satellite body, each gripping arm being pivotable relative to the satellite body, and a gripping end at each free end of the gripping arms, wherein the gripping ends are adapted and configured to capture and grip a target portion of an orbiting satellite. Each gripping arm is controllable independently by the controller, which coordinates the motion of the arms. The service satellite also includes a propulsion unit including a first thruster mounted adjacent a Nadir end of the service satellite body, and a balance thruster, the balance thruster being distanced from the first thruster and facing a different direction than the first thruster, propellant for the thruster and the balance thruster; and means for aligning the thrusters so that a thrusting vector passes through a joint center of gravity of the service satellite and the serviced satellite. 147-. (canceled)48. A service satellite for providing in-orbit services to an orbiting satellite , the service satellite comprising:a body;at least two thrusters;at least two docking arms connected to the body and configured to engage with an interface ring extending from an external surface of the orbiting satellite, each of the at least two docking arms including a ring-engaging end configured to couple with the interface ring; and move each of the at least two docking arms to enable the ring-engaging end of each of the at least two docking arms to couple with the interface ring at at least two spaced-apart locations on the interface ring, thereby forming an interconnection between the service satellite and the orbiting satellite through the externally extending interface ring, and thereby permitting the service satellite to join with the orbiting satellite, forming a tandem assembly; and', 'coordinate firing of the at ...

TECHNIQUES FOR PREDICTING SUBSEQUENT ATTACKS IN ATTACK CAMPAIGNS

A method and system for predicting subsequent cyber-attacks in attack campaigns are provided. The method includes receiving events data related to cyber-attacks occurring in a network during a predefined time window; extracting at least one sequence from the received events data at least one attack vector; generating a sequence signature for each of the at least one extracted sequence; comparing each sequence signature to a representation of historic sequence signatures to determine at least partially matching sequence signature; and based on the matching sequence, determining at least one subsequent cyber-attack in a respective sequence. 1. A method for predicting subsequent cyber-attacks in attack campaigns , comprising:receiving events data related to cyber-attacks occurring in a network during a predefined time window;extracting at least one sequence from the received events data at least one attack vector;generating a sequence signature for each of the at least one extracted sequence;comparing each sequence signature to a representation of historic sequence signatures to determine at least partially matching sequence signature; andbased on the matching sequence, determining at least one subsequent cyber-attack in a respective sequence.2. The method of claim 1 , wherein the sequence includes a series of cyber-attacks occurred during the same time window and against a target protected objects.3. The method of claim 1 , wherein generating the sequence signature for each of the at least one extracted sequence further comprises:performing an embedding process to generate the sequence signature.4. The method of claim 3 , wherein the embedding process is any one of: a neural network-based process and an n-grams-based process.5. The method of claim 4 , wherein the neural network-based embedding process includes:representing each cyber-attack in the extracted sequence as a vector of numbers encoded using attributes of the respective cyber-attack; andtransforming the ...

Medicinal Aerosol Formulations

The present invention provides a medical aerosol suspension formulation of MDI administration, comprising: a) micronized pa-agonist; b) micronized corticosteroid; c) a sib-therapextric quantity of a moisture-scavenger excipient; and d) a HFA propellant; wherein (a), (b), and (c) and their respective relative amounts are selected such that they associate to form floccules having a density substantially the same as that of the HFA propellant. 131-. (canceled)32. A method for preparing a stabilized medicinal aerosol suspension formulation for MDI administration , the formulation comprising:a) micronised formoterol fumarate dihydrate, or a pharmaceutically acceptable salt thereof, in an amount of 0.003-0.008% by weight of the total weight of the formulation;b) micronised fluticasone propionate or a pharmaceutically acceptable salt or derivative thereof in an amount of 0.01-0.6% by weight;c) a sub-therapeutic quantity of a moisture-scavenger excipient comprising sodium cromolyn in an amount of 0.01-0.1% by weight; andd) the propellant is HFA 227,{'sup': '3', 'the method comprising incorporating (a), (b), and (c) into the propellant in relative amounts selected such that (a), (b), and (c) associate to form floccules having an average density the same as the density of the HFA propellant ±0.2 g/cmand ensuring that the floccules are formed by'}removing a portion of the suspension for visual inspection,agitating the portion of the suspension,visually inspecting the agitated suspension for the formation of large loose floccules within five minutes of cessation of agitation,and determining that floccules are formed if visual inspection identifies the large loose floccules, wherein the floccules have a density substantially the same as that of the HFA propellant,wherein the method provides a formulation having stability over a storage period from 3 to 18 months and the water content of the formulation after the storage period is in the range of 500 ppm to 800 ppm.33. The method ...

AMYLIN ANALOGUES

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation. 132-. (canceled)33. A method of treating sleep apnea in a subject in need thereof , said method comprising orally administering to the subject an amylin analogue peptide , or a salt thereof , in an amount sufficient to treat the sleep apnea.34. A method of treating Alzheimer's disease in a subject in need thereof , said method comprising transdermally administering to the subject an amylin analogue peptide , or a salt thereof , in an amount sufficient to treat the Alzheimer's disease.36. The method of claim 35 , wherein X1 is selected from Arg and Lys.37. The method of claim 35 , wherein:(i) X3 is Gly, X4 is Thr, X5 is Ala and/or X6 is Thr;(ii) X3 is Gly, X4 is Thr, X5 is Ala and X6 is Thr;(iii) X14 is selected from His, Asp and Aad;(iv) X17 is Gln;(v) X19-X20 is selected from Ser-Ser and Thr-Thr, or is absent; or(vi) X32 is Val, X35 is Asn and/or X37 is Hyp.39. The method of claim 35 , wherein one of the residues at position X2 and X7 is selected from Asp claim 35 , Glu and Aad claim 35 , and the other is selected from Dap claim 35 , Dab claim 35 , Orn claim 35 , Lys and hLys.40. The method of claim 39 , wherein:X2 is Asp and X7 is Lys;X2 is Asp and X7 is Orn;X2 is Asp and X7 is Dab;X2 is Asp and X7 is hLys;X2 is Dap and X7 is Aad;X2 is Glu and X7 is Dab; orX2 is Dab and X7 is Glu.41. The method according to claim 40 , wherein:X2 is Asp and X7 is Lys; orX2 is Asp and X7 is Orn.42. The method according to claim 35 , wherein X14 is selected from Asp and Aad.44. The method of claim 35 , wherein Ris M or M-L-.45. The method of claim 44 , wherein M is a lipophilic ...

GLUCAGON ANALOGUES

The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation. 3. The compound or pharmaceutically acceptable salt or solvate thereof according to claim 1 , wherein said at least four amino acid substitutions or deletions at amino acid sequence positions (designated as X) selected from 2 claim 1 , 3 claim 1 , 4 claim 1 , 9 claim 1 , 10 claim 1 , 15 claim 1 , 16 claim 1 , 17 claim 1 , 20 claim 1 , 21 claim 1 , 24 claim 1 , 28 and 29 of the compound of formula I are as follows:X2 is selected from Aib and Ala;X3 is selected from His and Pro;X4 is DAla;X9 is Glu;X10 is selected from N-Me-Tyr and N-Me-DTyr;X15 is Glu;X16 is selected from Aib, Lys, Glu, Leu, Val, Phe, His and Arg;X17 is selected from Ala and Ser;X20 is selected from Glu and Lys;X21 is selected from Glu, Lys and Ser;X24 is selected from Lys, Ser, Glu and Ala;X28 is selected from Ser, Glu, and Lys, or is absent;X29 is selected from Ser and Ala, or is absent.4. The compound or pharmaceutically acceptable salt or solvate thereof according to claim 1 , wherein the at least four amino acid substitutions or deletions are at amino acid sequence positions (designated by an X) selected from 2 claim 1 , 3 claim 1 , 4 claim 1 , 10 claim 1 , 15 claim 1 , 16 claim 1 , 17 claim 1 , 20 claim 1 , 21 claim 1 , 24 claim 1 , 28 and 29 of the compound of formula I claim 1 , and are as follows:X2 is Ala;X3 is Dab(Ac), Dap(Ac) and Gln(Me);X4 is DAla;X10 is selected from Leu and Val;X15 is Glu;X16 is selected from Aib, Lys, Glu, Leu, and Val;X17 is Ala;X20 is selected from Glu and Lys;X21 is selected from Glu and Ser;X24 is selected from Lys, Ser and Glu;X28 is selected from Ser, Glu and Lys;X29 is Ala, or is absent.5. The compound or pharmaceutically acceptable salt or solvate thereof according to claim 1 , wherein the at least four amino acid ...

DEVICE AND METHOD FOR CHARACTERIZATION OF A LIGHT BEAM

A method for characterizing a light beam includes separating the light beam by a separator optic into first and second sub-beams; propagating the first and second sub-beams over first and second optics, respectively, said first and second optics being respectively arranged so that the sub-beams on leaving the optics are separated by a time delay τ; recombining the sub-beams so that they spatially interfere and form a two-dimensional interference pattern; measuring the frequency spectrum of at least part of the interference pattern; calculating the Fourier transform in the time domain of at least one spatial point of the frequency spectrum, the Fourier transform in the time domain having a time central peak and first and second time side peaks; calculating the Fourier transform in the frequency domain for one of the side peaks; calculating the spectral amplitude A(ω) and the spatial-spectral phase φ(x,y,ω) for the Fourier transform in the frequency domain. 1. A method for characterization of a light beam comprising:separating the light beam by means of a separator optic into a first sub-beam and a second sub-beam, the first sub-beam taking a first optical path and the second sub-beam taking a second optical path;propagating the first sub-beam over a first optic and the second sub-beam over a second optic, the first sub-beam having a non-homogeneous electromagnetic field over an entire surface of the first optic, said first and second optics being, thanks to a controller, respectively arranged in the first and second optical paths so that the first sub-beam on leaving the first optic, corresponding to a reference beam and the second sub-beam on leaving the second optic, corresponding to a characterized beam are separated by a time delay τ;recombining the reference beam and the characterized beam by means of a recombiner optic in such a way that the reference and characterized beams spatially interfere and form a two-dimensional interference pattern, the two- ...

Acylated glp-1/glp-2 dual agonists

A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

GLUCAGON ANALOGUES

The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation. 3. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein said at least four amino acid substitutions or deletions at amino acid sequence positions (designated as X) selected from 2 claim 1 , 3 claim 1 , 4 claim 1 , 9 claim 1 , 10 claim 1 , 15 claim 1 , 16 claim 1 , 17 claim 1 , 20 claim 1 , 21 claim 1 , 24 claim 1 , 28 and 29 of the compound of formula I are as follows:X2 is selected from Aib and Ala;X3 is selected from His and Pro;X4 is DAla;X9 is Glu;X10 is selected from N-Me-Tyr and N-Me-DTyr;X15 is Glu;X16 is selected from Aib, Lys, Glu, Leu, Val, Phe, His and Arg;X17 is selected from Ala and Ser;X20 is selected from Glu and Lys;X21 is selected from Glu, Lys and Ser;X24 is selected from Lys, Ser, Glu and Ala;X28 is selected from Ser, Glu, and Lys, or is absent; andX29 is selected from Ser and Ala, or is absent.4. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the at least four amino acid substitutions or deletions are at amino acid sequence positions (designated by an X) selected from 2 claim 1 , 3 claim 1 , 4 claim 1 , 10 claim 1 , 15 claim 1 , 16 claim 1 , 17 claim 1 , 20 claim 1 , 21 claim 1 , 24 claim 1 , 28 and 29 of the compound of formula I claim 1 , and are as follows:X2 is Ala;X3 is Dab(Ac), Dap(Ac) and Gln(Me);X4 is DAla;X10 is selected from Leu and Val;X15 is Glu;X16 is selected from Aib, Lys, Glu, Leu, and Val;X17 is Ala;X20 is selected from Glu and Lys;X21 is selected from Glu and Ser;X24 is selected from Lys, Ser and Glu;X28 is selected from Ser, Glu and Lys; andX29 is Ala, or is absent.5. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein the at least four amino acid substitutions or deletions are at ...

MEDICINAL AEROSOL FORMULATIONS

The present invention provides a process for making a stabilized medical aerosol suspension formulation for administration by a pressurized metered dose inhaler. 131-. (canceled)32. A method for preparing the medicinal aerosol suspension formulation for MDI administration , the formulation comprising:a) micronised formoterol fumarate or a pharmaceutically acceptable salt or derivative thereof in an amount of 0.003-0.04% by weight;b) micronised fluticasone propionate or a pharmaceutically acceptable salt or derivative thereof in an amount of 0.01-0.6% by weight;c) a sub-therapeutic quantity of a moisture-scavenger excipient comprising sodium cromolyn in an amount of 0.01-0.1% by weight; andd) the propellant HFA 227,the method comprising the step of incorporating sodium cromolyn into the formulation such that floccules of formoterol fumarate dihydrate, fluticasone propionate and sodium cromolyn are formed, wherein the floccules have a density substantially the same as that of the HFA propellant,wherein the method provides a formulation having stability over a storage period from 3 to 18 months and the water content of the formulation after the storage period is in the range of 500 ppm to 800 ppm.33. The method of claim 32 , wherein the amount of sodium cromolyn is from 0.01 to 0.1% claim 32 , the amount of formoterol fumarate dihydrate is from 0.003 to 0.04% claim 32 , and the amount of fluticasone propionate microparticles is from 0.01 to 0.6%.34. The method of claim 32 , wherein the average density of the floccules is substantially the same as the density of the propellant ±0.2 g/cm claim 32 , ±0.1 g/cm claim 32 , or ±0.5 g/cm.35. The method of claim 32 , wherein the pharmaceutical suspension formulation additionally comprises a wetting agent claim 32 , preferably a dehydrated alcohol claim 32 , preferably ethanol. The present invention relates to medicinal aerosol formulations for use with pressurised metered dose inhalers (abbreviated pMDI or MDI), and especially ...

TECHNIQUES FOR DEFENSING CLOUD PLATFORMS AGAINST CYBER-ATTACKS

A method and system for protecting a cloud computing platform against cyber-attacks are provided. The method includes gathering cloud logs from a cloud computing platform; analyzing, by a plurality of detectors, the cloud logs to detect at least one suspicious behavior, wherein each of the at least one suspicious behavior is identified by a suspect indicator; sequencing suspect indicators into attack sequences; scoring each of the attack sequences with an attack score, wherein each attack is scored using a scoring model; and alerting on each attack sequence having a score higher than a predefined threshold. 1. A method for protecting a cloud computing platform against cyber-attacks , comprising:gathering cloud logs from a cloud computing platform;analyzing, by a plurality of detectors, the cloud logs to detect at least one suspicious behavior, wherein each of the at least one suspicious behavior is identified by a suspect indicator;sequencing suspect indicators into attack sequences;scoring each of the attack sequences with an attack score, wherein each attack is scored using a scoring model; andalerting on each attack sequence having a score higher than a predefined threshold.2. The method of claim 1 , further comprising:performing a mitigation action to mitigate a cyber-attack represented by each attack sequence having a score higher than a predefined threshold.3. The method of claim 1 , wherein processing the cloud logs further comprises:normalizing the cloud logs.4. The method of claim 1 , wherein each of the plurality of detectors is configured to analyze the cloud logs to detect a different type of anomaly.5. The method of claim 1 , wherein analyzing the cloud logs to detect suspicious behavior further comprises:matching the cloud logs to threat intelligence information.6. The method of claim 1 , wherein analyzing the cloud logs to detect suspicious behavior further comprises:detecting suspicious behavior using a set of preconfigured rules.7. The method of ...

DEVICE AND METHOD FOR CHARACTERIZATION OF A LIGHT BEAM

A characterization method of a light beam includes separating the light beam into first and second sub-beams; propagating the first and second sub-beams over first and second optics respectively; the first sub-beam, which forms a reference beam, and the second sub-beam, which forms a characterized beam, being separated by a time delay τ; recombining the reference and characterized beams so that they spatially interfere and form a two-dimensional interference pattern; measuring the pattern to obtain a temporal interferogram; calculating the Fourier transform in the frequency domain of a spatial point of the interferogram, the Fourier transform having a frequency central peak and first and second frequency side peaks; calculating the Fourier transform in the frequency domain for the first or second time side peaks calculating the spectral amplitude and the spatial-spectral phase for the first or second frequency side peak of the Fourier transform in the frequency domain. 1. A method for characterization of a light beam , comprising:separating the light beam by means of a separator optic into a first sub-beam and a second sub-beam, the first sub-beam taking a first optical path and the second sub-beam taking a second optical path;{'b': 1', '1, 'propagating the first sub-beam over a first optic and of the second sub-beam over a second optic, the first sub-beam having an inhomogeneous electromagnetic field over the entire surface of the first optic, said first and second optics being, thanks to a control system means, respectively arranged in the first and second optical paths so that the first sub-beam on leaving the first optic, referred to as forming reference beam, and the second sub-beam on leaving the second optic, forming a characterized beam, are separated by a time delay τ sweeping a time interval T with a step P;'}recombining the reference beam and the characterized beam by means of a recombiner optic in such a way that the reference and the characterized beams ...

AMYLIN ANALOGUES

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation. 24-. (canceled)6. (canceled)811-. (canceled)12. An amylin analogue according to claim 1 , comprising the residues:X3 is Gly;X10 is selected from Glu and Asp;X14 is selected from His and Aad;X35 is selected from Gly and Asn; andX37 is selected from Pro and Hyp.13. An amylin analogue according to claim 1 , comprising the residues:Gly3+Glu10;Asn3+Glu10;Gln3+Glu10;Asn3+Gln10; orGln3+Asp10.14. An amylin analogue according to claim 1 , X14 is selected from His and Aad claim 1 , and/or X17 is Gln.15. An amylin analogue according to claim 1 , comprising the residues:Gln17+Glu31+Hyp37Gly3+Glu10+His14Asn3+Glu10+His14;Gln3+Glu10+His14;Gly3+Glu10+Aad14;Gly3+Glu10+Asp14;Asp10+Aad14;His14+Glu31+Pro37His14+Glu31+Hyp37Aad14+Glu31+Pro37;Aad14+Glu31+Hyp37;Gly3+Glu31; orGly3+Glu10+Glu31+Asn35+Hyp37.16. An amylin analogue according to claim 1 , X19-X20 is Ser-Ser.17. An amylin analogue according to claim 16 , comprising the residues:Gly3+Ser19+Ser20+Glu31 orGly3+Glu10+Ser19+Ser20+Glu31+Asn35+Hyp37.19. (canceled)20. An amylin analogue according to claim 1 , wherein Ris M- or M-L-.21. An amylin analogue according to claim 20 , wherein M is an alkanoyl group.22. An amylin analogue according to claim 21 , wherein M is selected from 15-carboxy-pentadecanoyl claim 21 , 17-carboxy-heptadecanoyl and 19-carboxy-nonadecanoyl.23. An amylin analogue according to claim 1 , Ris M-L- and L is a residue of an amino acid selected from the group consisting of Gly claim 1 , Pro claim 1 , Ala claim 1 , Val claim 1 , Leu claim 1 , Ile claim 1 , Met claim 1 , Cys claim 1 , Phe claim 1 , Tyr claim 1 , Trp ...

Auto-scaling virtual switches

A port is dynamically added to and removed from a virtual switch. The new port may be allocated when there is sufficient free memory in a pool of memory associated with the virtual switch. When an existing port is deallocated, the portion of the pool of memory allocated to that existing port is freed up. As a result, a virtual machine that requires one or more ports on the virtual switch may be provisioned on a host so long as the pool of memory is sized properly and memory usage on the host is not excessive.

Hardening of cloud security policies

A method and system for hardening cloud security policies of a cloud computing platform are presented. The method includes gathering cloud activity logs from at least the cloud computing platform, wherein the cloud computing platform includes a plurality of cloud entities; gathering a plurality of cloud security policies provisioned to protect the cloud entities; for each of the plurality of cloud security policies, generating a permission usage map, wherein the permission usage map represents the permissions granted to each cloud entity and the permissions used by each cloud entity; analyzing the permission usage map to discover at least one hardening gap, wherein each hardening gap is at least a difference between permissions granted and permissions used by a cloud entity; for each discovered hardening gap, computing a risk score designating a potential risk reduction achieved by addressing the hardening gap; generating at least one hardening recommendation for the at least one hardening gap and its respective computed risk score; and applying the at least one hardening recommendation to the respective cloud security policy, thereby hardening the cloud computing platform.

Formulations

In a metered dose inhaler, comprising a canister and metering valve, containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant, a method of reducing deposition of particles on the surfaces of the canister and the metering valve, the method comprising the step of adding a wetting agent to the formulation. 146-. (canceled)47. A method of reducing the deposition of drug particles of a suspension aerosol formulation on the surfaces of a canister and metering valve of a metered dose inhaler , the method comprising incorporating ethanol in an amount of less than 2% by weight based on the total weight of the formulation , the formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant , said particles having a mean aerodynamic particle diameter of from 1 to 6 microns.48. A method according to wherein the ethanol is employed in an amount of 1.99 to 0.01% by weight based on the total weight of the suspension aerosol formulation.49. A method according to wherein the ethanol is employed in an amount of 1.5% to 1.0% by weight based on the total weight of the suspension aerosol formulation.50. A method according to wherein the HFA propellant is HFA 227.51. A method according to wherein the formoterol fumarate dihydrate is employed in an amount of 0.003-0.04% by weight.52. A method according to wherein fluticasone propionate is employed in an amount of 0.01-0.6% by weight.53. A method according to wherein the suspension aerosol formulation comprises a salt selected from the group consisting of nedocromil and cromoglycic acid.54. A method according to wherein the salt is sodium cromoglycate (DSCG).55. A method according to wherein the sodium cromoglycate is employed in an amount of 0.01-0.1% by weight based on the total weight of the formulation.56. The method of claim 47 , wherein the canister after filling and being ...

Formulations

In a metered dose inhaler, comprising a canister and metering valve, containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant, a method of reducing deposition of particles on the surfaces of the canister and the metering valve, the method comprising the step of adding a wetting agent to the formulation. 1. In a metered dose inhaler , comprising a canister and metering valve , containing a suspension aerosol formulation comprising particles of formoterol fumarate dihydrate and fluticasone propionate suspended in an HFA propellant , a method of reducing deposition of particles on the surfaces of the canister and the metering valve , the method comprising the step of adding a wetting agent to the formulation.2. A method according to claim 1 , wherein the wetting agent is selected from the group consisting of ethanol claim 1 , diols or polyols claim 1 , such as propylene glycol claim 1 , glycerol claim 1 , butandiol and mixtures thereof.3. A method according to wherein the wetting agent is ethanol.4. A method according to wherein the wetting agent is employed in an amount of less than 2% by weight based on the total weight of the suspension aerosol formulation.5. A method according to wherein the wetting agent is employed in an amount of 1.99 to 0.01% by weight based on the total weight of the suspension aerosol formulation.6. A method according to wherein the wetting agent is employed in an amount of 1.5% to 1.0% by weight based on the total weight of the suspension aerosol formulation.7. A method according to wherein the HFA propellant is HFA 227.8. A method according to wherein the formoterol fumarate dihydrate is employed in an amount of 0.003-0.04% by weight.9. A method according to wherein fluticasone propionate is employed in an amount of 0.01-0.6% by weight.10. A method according to wherein the suspension aerosol formulation comprises a salt selected from the group ...

ACYLATED GLP-1/GLP-2 DUAL AGONISTS

A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction. 2. A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , wherein:X2 is Aib or G;X5 is T or S;X7 is T or S;X8 is S;X10 is L or ψ;X11 is A or S;X15 is D or E;X16 is G, E, A or ψ;X17 is Q, E, K, L or ψ;X19 is A or S;X20 is R or ψ;X21 is D, L or E;X24 is A;X27 is I, Q, K, or Y;X28 is Q, E, A, H, Y, L, K, R or S;X29 is H, Y or Q; andX33 is D or E.3. A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , wherein X16 is E and X17 is Q.4. A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , wherein:X11 is A and X15 is D;X11 is S and X15 is E; orX11 is A and X15 is E.5. A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , wherein X27 is I.6. A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , wherein X29 is H claim 1 , and optionally X28 is A or X28 is E.7. A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , wherein X29 is Q and optionally X27 is Q.8. A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , wherein the residues at X27-X29 have a sequence selected from:IQH;IEHIAH;IHH;IYH;ILH;IKH;IRH;ISH;QQH;YQH;KQH;IQQ;IQY;IQT; andIAY.10. A dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , wherein X16 is ψ and X17 is Q claim 1 , E claim 1 , K or L claim 1 , or X16 is G and X17 is ψ.11. A dual agonist or pharmaceutically acceptable salt ...

Production of soluble hiv envelope trimers in planta

The present invention relates to a method for producing a recombinant HIV glycoprotein polypeptide in a plant and to trimeric complexes of the recombinant, plant-produced HIV glycoprotein polypeptide which mimic the native HIV Env complex. The invention also relates to nucleic acids encoding the recombinant polypeptides, expression vectors containing the aforementioned nucleic acids and to pharmaceutical compositions, uses and methods of eliciting an immune response against HIV in a subject using the recombinant polypeptides and trimeric complexes.

GLP-1/GLP-2 DUAL AGONISTS

The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction. 2. A dual agonist or pharmaceutically acceptable salt thereof according to wherein:X2 is Aib;X5 is S or T;X7 is S or T;X8 is S or D;X10 is L;X11 is A or S;X15 is D or EX16 is E or G;X17 is Q or K;X19 is A or S;X20 is R;X21 is D or E;X24 is A, N or S;X27 is I, Y, Q or K;X28 is A, E, H, Y or L;X29 is H, Y or Q; andX33 is D.3. A dual agonist or pharmaceutically acceptable salt thereof according to wherein X2 is Aib claim 1 , X8 is S claim 1 , X7 is T claim 1 , X5 is T claim 1 , X29 is H and/or X27 is I.48-. (canceled)9. A dual agonist or pharmaceutically acceptable salt thereof according to wherein X27 is Q and X29 is Q oroptionally wherein X28 is A and X29 is H, oroptionally wherein X28 is E and X29 is H.1011-. (canceled)12. A dual agonist or pharmaceutically acceptable salt thereof according to wherein X11 is A claim 1 , and/or claim 1 , X16 is E and X17 is Q claim 1 , and/or X16 is G and X17 is K.13. (canceled)14. A dual agonist or pharmaceutically acceptable salt thereof according to wherein:X11 is S and X15 is E;X11 is Sand X19 is S;X11 is S and X21 is E;X15 is E and X19 is S;X15 is E and X21 is E;X11 is S, X15 is E and X19 is S;X11 is S, X15 is E and X21 is E;X11 is S, X19 is S and X21 is E;X15 is E, X19 is S and X21 is E; orX11 is S, X15 is E, X19 is S. and X21 is E.15. A dual agonist or pharmaceutically acceptable salt thereof according wherein residues X8-X24 contain a maximum of four changes compared to the sequence SELATILDEQAARDFIA (SEQ ID NO: 4).16. (canceled)17. A dual agonist or pharmaceutically acceptable salt thereof according to wherein the residues at X27-X29 have a sequence selected from:IAH;HAH;QAH;YAH;IAQ;MY;YEH;IQH;IKH; ...

PORTABLE AND TRACKABLE SECURITY BOX AND METHOD FOR DELIVERING AND TRACKING SECURITY BOX

A shipping box system and method are provided in which a shipping box has a container having a bottom surface and a plurality of walls, the container walls forming a perimeter about a container cavity. The shipping box further has a lid having a top surface and walls, the lid walls forming a perimeter about a lid cavity. The box further provides a sensor module for determining a physical location and orientation of the container, a computations module for evaluating data retrieved from the sensor module, and a locking assembly for locking the container and the lid in a closed configuration. The container and the lid are sized to nest, such that when the lid is fixed to the container, the container cavity and the lid cavity occupy substantially the same space and the container walls and the lid walls overlap. 1. A shipping box system comprising a first shipping box having:a container having a bottom surface and a plurality of container walls extending from the bottom surface, the container walls forming a perimeter about a container cavity;a lid having a top surface and a plurality of lid walls extending from the top surface, the lid walls forming a perimeter about a lid cavity;a sensor module for determining a physical location and orientation of the container;a computations module for evaluating data retrieved from the sensor module;a locking assembly for locking the container and the lid in a closed configuration;wherein the container and the lid are sized to nest, such that when the lid is fixed to the container, the container cavity and the lid cavity occupy substantially the same space and the container walls and the lid walls overlap.2. The shipping box system of claim 1 , wherein the perimeter about the lid cavity is larger than the perimeter about the container cavity claim 1 , such that the container is nested within the lid claim 1 , and wherein the container walls and the lid walls have substantially similar heights claim 1 , such that the container is ...

DEVICE AND METHOD FOR GENERATING A DRUG DATABASE

A device for generating a pivot drug database implemented in a computer system, the device includes an extraction unit configured for extracting the data from a set of elementary drug data sources, the elementary drug data sources storing drug-related data, each elementary data source being associated with a representation of the data; a structuring unit configured for structuring the extracted data by applying a pivot ontology to the extracted data, the pivot ontology defining classes derived from one or more ontologies of the drug and relationships between the classes, which provides structured data associated with a graph representing the relationships between the classes corresponding to the structured data; the device being configured for generating the pivot drug database according to the graph and the structured data, the pivot database storing the structured data. Applications: drug interaction analysis tools, tool for assisting medical prescription. 1. A device for generating a pivot drug database implemented in a computer system , the device comprising:an extraction unit configured for extracting the data from a set of elementary drug data sources, the elementary drug data sources storing drug-related data, each elementary data source being associated with a representation of the data;a structuring unit configured for structuring the extracted data by applying a pivot ontology to said extracted data, said pivot ontology defining classes derived from one or more ontologies of the drug and relationships between said classes, which provides structured data associated with a graph representing the relationships between the classes corresponding to said structured data;the device being configured for generating said pivot drug database according to said graph and said structured data, the pivot database storing said structured data.2. The device as claimed in claim 1 , wherein the extraction unit is configured for retrieving the data of the elementary data ...

ACYLATED GLP-1/GLP-2 DUAL AGONISTS

A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction. 1. A dual agonist represented by the formula:{'br': None, 'sup': 1', '2, 'R—X*—R,'}wherein:{'sup': '1', 'sub': '1-4', 'Ris hydrogen (Hy), Calkyl, acetyl, formyl, benzoyl or trifluoroacetyl;'}{'sup': '2', 'sub': '2', 'Ris NHor OH;'}X* is a peptide H[Aib]EGSFTSELATILDψQAARDFIAWLIQHKITD (SEQ ID NO: 38);{'sup': 1', '2', '1', '2, 'ψ is an L or D Lys residue whose side chain is conjugated to a substituent of formula Z—Z— and Z—Z— is [17-carboxy-heptadecanoyl]-isoGlu-, or a pharmaceutically acceptable salt thereof.'}4. A pharmaceutical composition comprising the dual agonist or pharmaceutically acceptable salt thereof according to claim 1 , in admixture with a pharmaceutically acceptable carrier claim 1 , an excipient or a vehicle.5. A pharmaceutical composition comprising the dual agonist or pharmaceutically acceptable salt thereof according to claim 3 , in admixture with a pharmaceutically acceptable carrier claim 3 , an excipient or a vehicle. Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 19, 2019 is named “50412-110004_Sequence_Listing_8.19.2019_ST25” and is 262,589 bytes in size.The present invention ...

Safety and life-saving device for aquatic environment

The invention concerns an inflatable grille, whereof the numerous openings are provided with open-worked netting, capable of being spaced apart and locked for rescuing in an aquatic environment someone stuck beneath the device to move onto the device and to clean the floor of a swimming pool more easily by inserting the vacuum cleaner in the netting openings which are capable of being spaced apart and locked. Said grille is associated with hoisting means adapted to the environment wherein it operates and in swimming pools with slide rails having a non-return system which blocks the device in high position.

Improved medicinal aerosol formulation

【課題】加圧定量吸入器（ｐＭＤＩまたはＭＤＩと略記）に使用するための医薬エアゾール製剤、特にエアゾール投与用の改善された医薬エアゾール製剤に関する。 【解決手段】ａ）微粒化β ２ −刺激薬、ｂ）微粒化コルチコステロイド、ｃ）準治療量の水分捕捉賦形剤およびｄ）ＨＦＡ噴射剤を含み、ここで（ａ）、（ｂ）および（ｃ）ならびにその各々の相対量は、これらが会合してＨＦＡ（ハイドロフルオロアルカン）噴射剤のものと実質的に同じ密度を有するフロキュールを形成するように選択されるＭＤＩ投与用医薬エアゾール懸濁液製剤の提供。 【選択図】なし

Reagent and method for attaching target molecules to a surface

Method and reagent composition for covalent attachment of target molecules, such as nucleic acids, onto the surface of a substrate. The reagent composition includes groups capable of attracting the target molecule as well as groups capable of covalently binding to the target molecule, once attracted. Optionally, the composition can contain photoreactive groups for use in attaching the reagent composition to the surface.

Process for the preparation of phenolic resin foams using a microwave-sensitive material, foam structure produced by this process and their use

Verfahren zur Herstellung von Phenolharz-Schäumen, umfassend folgende Schritte: Bereitstellen einer Mischung umfassend: – ein polymerisierbares System; und – gegenüber Mikrowellen empfindliche Partikel als Nukleierungsmittel, um eine homogene Porenbildung zu fördern, wobei die gegenüber Mikrowellen empfindlichen Partikel ausgewählt sind aus der Gruppe bestehend aus Carbon Nanosphere Chains, Carbon Nanotubes, Ruß, Graphit, Graphen und Siliciumcarbid Aktivieren der gegenüber Mikrowellen empfindlichen Partikel mittels Bestrahlung durch Mikrowellen, wobei die gegenüber Mikrowellen empfindlichen Partikel lokal erwärmt werden und als Nukleierungsmittel für eine kontrollierte und gleichmäßige Porenbildung dienen; und Aufschäumen des polymerisierbaren Systems mittels durch die initiierte Vernetzung des polymerisierbaren Systems freigesetzten Hydrolyseproduktes Wasser als Treibmittel.

Biodegradable adhesive packaging

A method and composition of packaging an adhesive composition, especially a thermoplastic or thermosetting hot melt adhesive. The method comprises the steps of providing one substantially uniform separate portion of the adhesive composition; sufficiently solidifying said portion for packaging; and substantially completely surrounding said sufficiently solidified portion with a biodegradable polymeric packaging material. The packaging material being meltable together with the adhesive composition and blendable into said molten adhesive composition, the kind and amount of said biodegradable packaging material being chosen so as not to disadvantageously affect the properties of the adhesive composition when blended into the molten adhesive and applied to a substrate.

FLUID INJECTION DEVICE.

L'invention concerne un injecteur comportant une aiguille (4) montée dans une buse (3) étant liée à un actionneur (2) comportant une première (21), une deuxième (22) et une troisième (23) parties, les première (21) et troisième (23) parties étant disposées de part et d'autre de la deuxième partie (22), les trois parties étant serrées ensemble pour former un bloc présentant deux limites opposées (C), (D), la première partie (21) étant liée avec l'aiguille (4) à l'endroit d'une (D) des dites limites (C), (D), des moyens d'excitation (14) mettant la deuxième partie (22) en vibrations avec une période tau.Selon l'invention, la longueur (L) entre les deux limites (C), (D) est telle que le temps de propagation T des ondes acoustiques parcourant cette longueur (L) répond à l'équation : T = n*[tau/2], où n est un coefficient multiplicateur, entier positif non nul. The invention relates to an injector comprising a needle (4) mounted in a nozzle (3) being connected to an actuator (2) comprising a first (21), a second (22) and a third (23) part, the first (21) and 21) and third (23) portions being disposed on either side of the second portion (22), the three portions being clamped together to form a block having two opposite boundaries (C), (D), the first portion ( 21) being connected with the needle (4) at one (D) of said limits (C), (D), excitation means (14) putting the second part (22) in vibration with According to the invention, the length (L) between the two limits (C), (D) is such that the acoustic wave propagation time T traveling along this length (L) corresponds to the equation: T = n * [tau / 2], where n is a multiplier coefficient, nonzero positive integer.

AUGMENTED REALITY PROCESS AND SYSTEM

Un dispositif informatique de réalité augmentée, par la suite désigné sous le nom de dispositif AR dans la présente, comprenant un ou plusieurs processeurs configurés pour recevoir des informations liées à un objet amovible, vérifier si une représentation de l'objet fait partie d'une représentation de l'environnement virtuel l'environnement occupé par le dispositif et l'écran AR, dans une portion de l'écran visible pour un utilisateur de l'information du dispositif AR relative à l'objet. An augmented reality computing device, hereinafter referred to as an AR device herein, comprising one or more processors configured to receive information related to a removable object, verifying whether a representation of the object is part of a representation of the virtual environment the environment occupied by the device and the screen AR, in a portion of the screen visible to a user of the information of the device AR relating to the object.

Compositions comprising at least one compound from the family of N-acylamino-amides and at least one alkylpolyglycoside

Composition comprenant au moins un composé de la famille des N-acylamino-amides et au moins un alkylpolyglycoside L’invention concerne une composition, notamment cosmétique, de préférence sous la forme d’émulsion huile-dans-eau, comprenant: - au moins un composé de la famille des N-acylamino-amides de formule (I) ;[Chem 10] - au moins un alkylpolyglycoside de formule (IV) suivante :R9(O)(G)x (IV)dans laquelle le radical R9 est un radical alkyle linéaire ou ramifié en C14-C24,G représente un sucre réduit comportant de 5 à 6 atomes de carbone, etx désigne une valeur allant de 1 à 10, de préférence de 1 à 4.Particulièrement ladite composition comprenant en outre au moins un composé choisi parmi les esters de sorbitan oxyéthylénés et les esters d’acide gras et de polyoxyalkylène glycol. Application au soin, maquillage et/ou nettoyage des matières kératiniques, notamment la peau]

Composition comprising a monoglyceride, a tartaric ester of monoglyceride and a derivative of salicylic acid

Composition comprenant un monoglycéride, un ester tartrique de monoglycéride et un dérivé d’acide salicylique L’invention concerne une composition, de préférence cosmétique, comprenant au moins une phase aqueuse, au moins un monoglycéride, au moins un ester tartrique de monoglycéride, et au moins un dérivé d’acide salicylique. L’invention concerne aussi un procédé de traitement cosmétique dans lequel on applique une composition telle que définie selon l’invention sur les matières kératiniques, et en particulier sur la peau. L’introduction de dérivés d’acide salicylique dans une composition comprenant au moins une phase aqueuse, au moins un monoglycéride, et au moins un ester tartrique de monoglycéride, non seulement n’entraine pas leur déstabilisation mais permet également d’améliorer l’absorption cutanée de ces actifs et ainsi d’augmenter leur efficacité. Composition comprising a monoglyceride, a tartaric ester of monoglyceride and a derivative of salicylic acid The invention relates to a composition, preferably cosmetic, comprising at least one aqueous phase, at least one monoglyceride, at least one tartaric ester of monoglyceride, and at least one minus a derivative of salicylic acid. The invention also relates to a cosmetic treatment process in which a composition as defined according to the invention is applied to keratin materials, and in particular to the skin. The introduction of salicylic acid derivatives into a composition comprising at least one aqueous phase, at least one monoglyceride, and at least one tartaric ester of monoglyceride, not only does not cause their destabilization but also makes it possible to improve absorption. skin of these assets and thus increase their effectiveness.

FLUID INJECTION DEVICE.

Dispositif d'injection de fluide (131 ) présentant un axe principal d'injection (AB) et comportant au moins :- un boîtier (1 ),- un actionneur (2) monté axialement dans le boîtier (1) et présentant un empilement avec deux faces frontales opposées (C), (D) axialement et incluant au moins une partie électroactive (22) comportant un matériau électroactif (221 ), et- un moyen de précontrainte adapté à précontraindre au moins partiellement ledit empilement,Selon l'invention, le moyen de précontrainte comprend au moins une bride de serrage (25) externe à l'empilement et disposée entre l'empilement et le boîtier (1 ). Fluid injection device (131) having a main injection axis (AB) and comprising at least: - a housing (1), - an actuator (2) axially mounted in the housing (1) and having a stack with two opposite end faces (C), (D) axially and including at least one electroactive part (22) comprising an electroactive material (221), and a prestressing means adapted to preload at least partially said stack, according to the invention, the prestressing means comprises at least one clamping flange (25) external to the stack and arranged between the stack and the housing (1).

AUGMENTED REALITY METHOD AND SYSTEM

Un dispositif informatique de réalité augmentée, par la suite désigné sous le nom de dispositif AR dans la présente, comprenant un ou plusieurs processeurs configurés pour recevoir des informations liées à un objet amovible, vérifier si une représentation de l'objet fait partie d'une représentation de l'environnement virtuel l'environnement occupé par le dispositif et l'écran AR, dans une portion de l'écran visible pour un utilisateur de l'information du dispositif AR relative à l'objet. An augmented reality computing device, hereinafter referred to as an AR device herein, comprising one or more processors configured to receive information related to a removable object, check whether a representation of the object is part of a representation of the virtual environment the environment occupied by the device and the AR screen, in a portion of the screen visible to a user of the information of the AR device relating to the object.

fluid i.e. fuel, injecting device i.e. fluid injector, for internal combustion engine, has stack fixed to needle in fixation zones that are axially distant from one another along needle

The device has an actuator (2) with an stack (20) traversed by an axial passage (200) and provided with frontal surfaces (C, D) that are axially opposed to one another. A filiform needle (4) is partially housed in the passage and projected from the stack at the side of the surface (D). A pre-stressing unit has an elastic unit e.g. rubber joint, and a coupling sleeve to apply axial stress on the stack. The stack is fixed to the needle in fixation zones (51, 52) that are axially distant from one another along the needle. The zone (51) is formed by a support zone of the surface (D) on a stopper.

THERMOFUSIBLE ELASTIC GLUE APPROPRIATE IN PARTICULAR TO THE PRODUCTION OF ELASTIC BELTS ON COMPLETE CHANGES.

Colle thermofusible élastique appropriée notamment à la réalisation de ceintures élastiques sur des changes complets. Cette colle comprend: a) au moins un caoutchouc synthétique de type bloc copolymère comportant au moins un bloc médian caoutchouteux et au moins deux blocs terminaux vitreux; b) au moins une résine tackifiante s'associant au bloc médian dudit bloc copolymère; c) au moins une résine tackifiante s'associant aux blocs terminaux; d) au moins une huile minérale, mise en œuvre à raison de 5 à 35 % en poids de la composition. Elastic hot-melt adhesive suitable in particular for the production of elastic belts on complete diapers. This adhesive comprises: a) at least one synthetic rubber of the copolymer block type comprising at least one rubbery middle block and at least two glassy end blocks; b) at least one tackifying resin associating with the middle block of said copolymer block; c) at least one tackifying resin associating with the terminal blocks; d) at least one mineral oil, used in an amount of 5 to 35% by weight of the composition.

Carburetor

ZEOLITHE TI-BETA, ITS PREPARATION METHOD AND ITS USE AS AN OXIDATION CATALYST

High voltage central electrode for radiofrequency plasma generation spark plug, has stem connected to plug`s coil, where electrode is made of nickel and coil has one end turn connected to inner end of electrode by connection system

The electrode (3) has a cylindrical body (19) including a circular section with an axis (Z), and a transversal stem connected to a coil (5) of a radiofrequency plasma generation spark plug, where the electrode is made of nickel. The stem is fixed to a high end part of the body and is made of silver. The coil has an end turn (51a) connected to a connector (12) and another end turn (51b) connected to an inner end of the electrode by a connection system (14). Independent claims are also included for the following: (1) a method for mounting an electrode on an insulator of a radiofrequency plasma generation spark plug (2) a method for fabricating an electrode.

Compositions comprising at least one compound of the N-acylamino-amide family and at least one alkylpolyglycoside

Composition comprenant au moins un composé de la famille des N-acylamino-amides et au moins un alkylpolyglycoside L’invention concerne une composition, notamment cosmétique, de préférence sous la forme d’émulsion huile-dans-eau, comprenant: - au moins un composé de la famille des N-acylamino-amides de formule (I) ;[Chem 10] - au moins un alkylpolyglycoside de formule (IV) suivante :R9(O)(G)x (IV)dans laquelle le radical R9 est un radical alkyle linéaire ou ramifié en C14-C24,G représente un sucre réduit comportant de 5 à 6 atomes de carbone, etx désigne une valeur allant de 1 à 10, de préférence de 1 à 4.Particulièrement ladite composition comprenant en outre au moins un composé choisi parmi les esters de sorbitan oxyéthylénés et les esters d’acide gras et de polyoxyalkylène glycol. Application au soin, maquillage et/ou nettoyage des matières kératiniques, notamment la peau] Composition comprising at least one compound of the N-acylamino-amide family and at least one alkylpolyglycoside The invention relates to a composition, in particular cosmetic, preferably in the form of an oil-in-water emulsion, comprising: - at least one compound of the family of N-acylamino-amides of formula (I); [Chem 10] - at least one alkylpolyglycoside of formula (IV) below: R9 (O) (G) x (IV) in which the radical R9 is a linear or branched C14-C24 alkyl radical, G represents a reduced sugar comprising from 5 to 6 carbon atoms, and x denotes a value ranging from 1 to 10, preferably from 1 to 4, particularly said composition further comprising at least one compound chosen from oxyethylenated sorbitan esters and fatty acid esters of polyoxyalkylene glycol. Application to the care, makeup and / or cleansing of keratin materials, in particular the skin]

IGNITION CANDLE FOR INTERNAL COMBUSTION ENGINE

Bougie d'allumage (1 ) pour le moteur à combustion interne d'un véhicule automobile, de forme générale sensiblement cylindrique, comportant :- une partie inférieure essentiellement capacitive (C) comportant :● deux électrodes coaxiales : une électrode interne d'axe (D) appelée électrode centrale (3) et une électrode externe appelée culot (2) entourant l'électrode centrale (3)● un bloc isolant électriquement, appelé isolant (4) interposé entre l'électrode centrale (3) et le culot (2),- une partie supérieure essentiellement inductive (1) comportant :● un mandrin (8) central entouré d'un bobinage (5), dont une partie d'extrémité basse (57) entoure une partie d'extrémité haute (31) de l'électrode centrale (3)● une enveloppe externe (6),● un isolant (7) interposé radialement entre l'enveloppe(6) et le bobinage (5) caractérisée en ce que la partie d'extrémité haute (31) de l'électrode centrale (3) comporte un revêtement (9) de matériau qui:- présente une conductivité électrique supérieure à celle du matériau de l'électrode centrale (3),- ne présente pas de propriétés ferromagnétiques.

FLUID INJECTION DEVICE.

COMPOSITION COMPRISING UV FILTER, ACRYLIC COPOLYMER AND ACRYLAMIDO METHYLPROPANE SULFONIC ACID COPOLYMER

La présente invention concerne une composition, notamment cosmétique, en particulier photoprotectrice, comprenant au moins : - un ou plusieurs polymères hydroxyéthyleacrylate - un ou plusieurs filtres UV, et - un ou plusieurs copolymères d'acide acrylamido-2-méthyl propane sulfonique et d'un ou plusieurs monomères non ioniques. The present invention relates to a composition, in particular cosmetic, in particular photoprotective, comprising at least: - one or more hydroxyethyleacrylate polymers - one or more UV filters, and - one or more copolymers of acrylamido-2-methyl propane sulfonic acid and of one or more nonionic monomers.

Composition comprising low molecular weight hyaluronic acid, polyglycerol ester and sclerotium gum

Composition comprenant de l’acide hyaluronique de faible poids moléculaire, un ester polyglycérolé et une gomme de sclérotium La présente invention concerne une composition aqueuse, de préférence cosmétique, comprenant de l’acide hyaluronique et/ou un de ses sels de faible poids moléculaire, au moins un ester d’acide gras et de polyglycérol comprenant de 5 à 9 motifs de glycérol, et au moins 0,2% en poids par rapport au poids total de composition d’une gomme de sclérotium. Figure pour l'abrégé : néant Composition comprising low molecular weight hyaluronic acid, a polyglycerolated ester and a sclerotium gum The present invention relates to an aqueous composition, preferably cosmetic, comprising hyaluronic acid and/or one of its low molecular weight salts, at least one fatty acid polyglycerol ester comprising from 5 to 9 glycerol units, and at least 0.2% by weight relative to the total composition weight of a sclerotium gum. Figure for the abstract: none

Improved accumulator device, forming a block, for the total supply of thermionic tubes

Method of packaging an adhesive composition and corresponding packaged article

Amylin analogues

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

A method of packaging an adhesive composition and the composition of the packaging

A method and composition of packaging an adhesive composition, especially a thermoplastic or thermosetting hot melt adhesive. The method comprises the steps of providing one substantially uniform separate portion of the adhesive composition; sufficiently solidifying said portion for packaging; and substantially completely surrounding said sufficiently solidified portion with a biodegradable polymeric packaging material. The packaging material being meltable together with the adhesive composi-tion and blendable into said molten adhesive composition, the kind and amount of said biodegradable packaging material being chosen so as not to disadvantageously affect the properties of the adhesive composition when blended into the molten adhesive and applied to a substrate.

SYNTHESIS OF AN ISOMORPHIC SILICOALUMINOTITANATE TO ZEOLITE BETA, ACTIVE FOR THE SELECTIVE OXIDATION OF ORGANIC COMPOUNDS.

SINTESIS DE UN SILICOALUMINOTITANATO ISOMORFO A LA ZEOLITA BETA, ACTIVO PARA LA OXIDACION SELECTIVA DE COMPUESTOS ORGANICOS. EL MATERIAL USADO COMO FUENTE DE TIOSI2 SE HIDROLIZA EN UNA DISOLUCION ACUOSA DE TETRAETILAMONIO, SE DILUYE CON AGUA, Y EN LA DISOLUCION RESULTANTE SE HIDROLIZA EL REACTIVO FUENTE DE Y, (P.E., SILICE); A LA MEZCLA OBTENIDA SE AÑADE CON AGITACION UNA DISOLUCION CONTENIENDO LA FUENTE DE XSI2OSI3 (ALSI2OSI3 O (NOSI3)SI3AL); EL GEL RESULTANTE SE CALIENTA EN AUTOCLAVE A TEMPERATURA ENTRE 80 Y 200GC. LOS SILICOALUMINOTITANATOS OBTENIDOS, ISOMORFOS A LA ZEOLITA BETA, SON ACTIVOS PARA LA OXIDACION SELECTIVA DE COMPUESTOS ORGANICOS; DESPUES DE ACTIVARLO POR CALCINACION ENTRE 350 Y 800GC SON CAPACES DE OXIDAR SELECTIVAMENTE ALCANOS LINEALES Y RAMIFICADOS Y CICLOALCANOS A ALCOHOLES Y CETONAS, FENOL A CATECOL E HIDROQUINONA, Y ALQUENOS A EPOXIDOS; CON UN INTERCAMBIO POSTERIOR CON H'' O PRECURSORES DE LOS MISMOS, PERMITE PREPARAR CATALIZADORES BIFUNCIONALES OXIDANTE-ACIDO/BASE.

Method of packaging hot melt adhesive and packaged adhesive composition

Method of packing an adhesive composition and corresponding packaged article

The invention relates to a method of packaging an adhesive composition, especially a thermoplastic or thermosetting hot melt adhesive, and to correspondingly packaged adhesives. The method comprises the steps of providing one substantially uniform separate portion of the adhesive composition; sufficiently solidifying said portion for packaging; substantially completely surrounding said sufficiently solidified portion with a plastics packaging material; the packaging material being meltable together with the adhesive composition and blendable into said molten adhesive composition, the kind and amount of said packaging material being chosen so as not to disadvantageously affect the properties of the adhesive composition when blended into same. Preferably, the packaging material is a net, a wrap, a sack or a bag. Packagings made of plastic film are advantageously voided of air, to prevent problems in melting. The packaged adhesive can be melted as it is.

A high voltage direct current cable termination apparatus

A direct current cable termination apparatus for terminating a high voltage direct current cable, the apparatus comprises a current-carrying device (102) comprising a terminal portion (104) of the direct current cable, the cable at least comprising an electrical conductor (106), a electrically insulating layer (108) located outside of the electrical conductor, and a conductive shield (110) located outside of the insulating layer and the electrical conductor; and a housing (111 ) comprising a tubular outer shell (112) with an inner periphery (114) and formed by an electrically insulating and polymer-containing material. The current-carrying device (102) is adapted to extend in the axial direction of the outer shell. Along at least a part of the axial extension of the current-carrying device the outer shell extends axially with a space (118) between its inner periphery (114) and the current-carrying device (102). The housing is adapted to separate the space (1 18) from an atmosphere outside (120) the outer shell, and the space is filled with an electrically insulating fluid (125; 266). The outer shell (1 12) has a first end portion (132) and a second end portion (134). The apparatus comprises at least one electric field control member (128) located at a first axial range (146) from the first end portion (132) and at a second axial range (148) from the second end portion (134). The conductive shield (1 10) terminates inside the outer shell. The electric field control member (128) is provided inside the outer shell. A first part (142) of the terminal portion (104) of the cable has the conductive shield (110), whereas a remainder part (144) of the terminal portion (104) of the cable has the conductive shield removed, the first part (142) being situated outside the first axial range (146). The apparatus comprises at least one field grading material layer (150) positioned around the current-carrying device (102), the at least one field grading material layer being ...

Electronic system having several removable units

ABREGE Système électronique à plusieurs unités amovibles L'invention se situe dans le domaine des systèmes électroniques comportant plusieurs unités amovibles qui communiquent entre elles par un bus. Pour pouvoir effectuer la déconnexion ou la connexion des unités amovibles sans interrompre le fonctionnement du système, chaque unité comprend des premiers moyens (4) commandes sélectivement par un dispositif de maintenance pour assurer l'isolement fonctionnel des unités amovibles. De plus, le système comprend des seconds moyens (8, 1B) capables de faire fonctionner les dispositifs de réception (1) des unités selon un mode qui leur procure une immunité accrue aux perturbations. Application notamment aux systèmes informatiques. SHORT Electronic system with several removable units The invention relates to the field of electronic systems comprising several removable units which communicate with each other by a bus. To be able to disconnect or connect the removable units without interrupting the operation of the system, each unit includes first means (4) selectively controlled by a device maintenance to ensure the functional isolation of the removable units. Of more, the system comprises second means (8, 1B) capable of making operate the receiving devices (1) of the units in a mode which gives them increased immunity to disturbance. Application in particular to computer systems.

Procedure for packaging a hot melt adhesive and packaged adhesive composition

Glucagon analogues

The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.

Power capacitor unit for high pressure applications

ELECTRONIC SYSTEM WITH MULTIPLE REMOVABLE UNITS

Pharmaceutical composition of glp-1/glp-2 dual agonists

The present invention relates to pharmaceutical compositions comprising particular preservatives.

Fluid injection device

The invention relates to an injector including a needle mounted in a nozzle and having an end defining a valve, the needle being connected at the other end to an actuator including first, second and third portions, the first and third portions being provided on either side of the second portion, the three portions being tightened together in order to form a block having two axially opposite limits, the first portion being connected with the needle at one of said limits, and an excitation means for vibrating the second portion according to setpoint period τ. According to the invention, the length between the two limits of the block is such that the propagation time T of the acoustic waves generated by the vibrations of the second portion of the actuator and running along that length meets the equation: T = n*[τ/2], where n is an integer positive multiplication coefficient different from zero.

Catheter including anti-microbial sleeve and catheter manufacturing method

【課題】新規な構成を有する医療用カテーテルおよびその作成方法を提供する。 【解決手段】外面を有する管状本体１２、およびその管状本体の外面の一部分のみの上に配置されたスリーブ６０を備える。これらカテーテルは、水溶性の抗微生物剤を含む抗微生物外側スリーブ６０を備える。これらカテーテルは、異なる医療適用のために種々の構成を有し得る。例えば、これらカテーテルは、正中カテーテル；血液透析カテーテル（長期または短期）のような中央静脈カテーテル；静脈内（ＩＶ）カテーテル；末梢挿入中央カテーテル（ＰＩＣＣ）；Ｆｏｌｙカテーテルのような泌尿器科学カテーテルなどであり得る。 【選択図】図１

Support device for furniture

Amylin analogues

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

POWER CAPACITOR UNIT FOR HIGH PRESSURE APPLICATIONS

UNIDADE DE CAPACITOR DE POTÊNCIA PARA APLICAÇÕES A ALTA PRESSÃO. A presente invenção se refere a uma unidade de capacitor de potência (1) para aplicações a alta pressão. A unidade de capacitor de potência (1) compreende um alojamento (3), uma pluralidade de elementos de capacitor (5 - 17, 23 - 35) conectados uns aos outros e dispostos no interior do alojamento (3), um líquido dielétrico (L), um sistema de isolamento elétrico sólido disposto de modo a isolar eletricamente cada elemento de capacitor (5 - 17, 23 - 35), um barramento, uma pluralidade de fios de fusível (5a - 17a), cada fio de fusível tendo uma primeira extremidade conectada a um respectivo elemento de capacitor (5 - 17, 23 - 35) e uma segunda extremidade conectada ao barramento (B), sendo que os elementos de capacitor (5 - 17, 23 - 35), o sistema de isolamento elétrico sólido (41), e os fios de fusível (5a - 17a) ficam imersos no líquido dielétrico (L). Cada fio de fusível (5a - 17a) tem uma pluralidade de primeiras seções que ficam em contato físico com o sistema de isolamento elétrico, e sendo que cada fio de fusível (5a - 17a) tem uma pluralidade de segundas seções sem contato fisico com o sistema de isolamento elétrico sólido. POWER CAPACITOR UNIT FOR HIGH PRESSURE APPLICATIONS. The present invention relates to a power capacitor unit (1) for high pressure applications. The power capacitor unit (1) comprises a housing (3), a plurality of capacitor elements (5 - 17, 23 - 35) connected to each other and arranged inside the housing (3), a dielectric liquid (L ), a solid electrical insulation system arranged to electrically insulate each capacitor element (5 - 17, 23 - 35), a busbar, a plurality of fuse wires (5a - 17a), each fuse wire having a first end connected to a respective capacitor element (5 - 17, 23 - 35) and a second end connected to the busbar (B), whereby the capacitor elements (5 - 17, 23 - 35), the solid electrical insulation system (41), and the fuse wires (5a - 17a) are immersed in the ...

Pharmaceutical composition of glp-1/glp-2 dual agonists

The present invention relates to pharmaceutical compositions comprising particular preservatives.

Safety and life-saving device for aquatic environment

Grille gonflable, dont les multiples ouvertures sont munies de filet avec ajourages écartables et verrouillables permettant non seulement le sauvetage en milieux aquatiques à quelqu'un de coincé sous le dispositif de passer sur le dispositif et en piscine de nettoyer le fond plus facilement en introduisant le bras de l'aspirateur dans les ajourages écartables et verrouillables, elle est associée à des moyens de levage adaptés au milieu dans lequel elle doit opérer et en piscine à des glissières avec système anti-retour qui bloque le dispositif en position haute.

composition and non-therapeutic process for photoprotection

A presente invenção refere-se a uma composição, especialmente uma composição cosmética, em particular fotoprotetora, composição, compreendendo pelo menos um ou mais polímeros de acrilato de hidroxietila, um ou mais agentes de proteção contra UV, e um ou mais copolímeros de ácido acrilamido-2-metilpropanossulfônico e um ou mais monômeros não-iônicos. The present invention relates to a composition, especially a cosmetic composition, in particular a photoprotective composition, comprising at least one or more hydroxyethyl acrylate polymers, one or more UV protecting agents, and one or more acrylamide acid copolymers -2-methylpropanesulfonic and one or more nonionic monomers.

Amylin analogues.

La presente invención se refiere a análogos de amilina y a su uso en el tratamiento o la prevención de varias enfermedades, afecciones o trastornos, incluyendo obesidad, consumo excesivo de alimentos y enfermedades metabólicas asociadas tales como diabetes. Los análogos tienen una buena estabilidad física y química, una buena solubilidad y una larga duración de acción, y son adecuados para su uso en forma de una formulación líquida.

Amylin analogues

The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Opening rear window for motor vehicle, has supply terminals of electrical conductors, defrosting heating assembly and locking control unit arranged on separate places that are provided on glazed surface in distinct humid zones

The window (7) has an electrical conductor (11) screen printed in a glazed surface and connected to supply terminals provided on the window. The supply terminals of the electrical conductors, a defrosting heating assembly (10) and a locking control unit (9) are arranged on places that are provided on the glazed surface in distinct humid zones. The defrosting heating assembly and the locking control unit of the glazed surface are arranged with respect to a cab interior (1).

Acylated GLP-1/GLP-2 dual agonists

A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Medium-frequency transformer with dry core

A transformer (1) is provided, which comprises a tank (10) having an enclosed volume (11) with an insulating material (13), the tank (10) comprising at least one channel (25) extending through the tank (10), wherein the interior of the at least one channel (25) is separated from the enclosed volume (11) of the tank (10) by a channel wall (17). A transformer core (30) is provided outside of the enclosed volume (11), comprising at least one core leg (32) extending through the tank (10) via the at least one channel (25). At least one coil (50, 52) is located inside the enclosed volume (11), the coil (50, 52) being wound about the at least one channel (25), wherein the tank (10) has an inner wall or outer wall (16) comprising a weakly- conductive layer (40), which comprises fibers (42) embedded in an impregnating material (44).

Process for packing a glue composition and the products packed

Silicoaluminophosphates having AEL topology

Beak and feather disease virus sequences, compositions and vaccines and the use thereof in therapy, diagnosis and assays

EMULSION OF RESVERATROL

La présente invention concerne une composition, notamment cosmétique, de type émulsion et comprenant : - au moins 0,5 % en poids, de préférence au moins 1 % en poids de resvératrol par rapport à son poids total, - au moins un homo- ou co-polymère de vinylpyrrolidone (PVP), et - au moins une huile hydrocarbonée solubilisante dudit resvératrol. The present invention relates to a composition, in particular cosmetic, of emulsion type and comprising: - at least 0.5% by weight, preferably at least 1% by weight of resveratrol relative to its total weight, - at least one homo- or co-polymer of vinylpyrrolidone (PVP), and - at least one solubilizing hydrocarbon oil of said resveratrol.

High voltage direct current cable termination apparatus

A direct current cable termination apparatus for terminating a high voltage direct current cable. The apparatus includes a current-carrying device including a terminal portion of the direct current cable, the cable including an electrical conductor, an electrically insulating layer located outside of the electrical conductor, and a conductive shield located outside of the insulating layer and the electrical conductor; and a housing including a tubular outer shell with an inner periphery and formed by an electrically insulating and polymer-containing material. The current-carrying device is adapted to extend in the axial direction of the outer shell. Along at least a part of the axial extension of the current-carrying device the outer shell extends axially with a space between its inner periphery and the current-carrying device.

Glp-1/glp-2 dual agonists

The invention relates to compounds having agonist activity at the GLP-1 (glucagon- like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

Modified electrode for the electrocatalytic oxidation of alcohols (Machine-translation by Google Translate, not legally binding)

Electrode modified for the electrocatalytic oxidation of alcohols. The present invention provides a complex of a divalent or trivalent metal of the periods 4, 5 and 6 and a tetradentate ligand of the formula (I) Wherein r 1 , r 2 , r 3 and r 4 are independently a hydrogen atom or a hydroxyl group, with the proviso that two of r 1 , r 2 , r 3 and r 4 are a hydroxyl group in ortho or para position and with the proviso that the metal is not copper. Also, the invention provides a modified electrode comprising a conductive substrate coated with a polymeric film of said complex; as well as a method for the preparation of said electrode and the use thereof to catalyze the electrooxidation of short chain aliphatic alcohols. (Machine-translation by Google Translate, not legally binding)